QURE: $5.4M Bear Call Spread (Nov 5)

💊 QURE Massive $5.4M Bear Call Spread - Smart Money Betting Against Recovery Rally!

🎯 The Quick Take

Someone just laid down $5.4 MILLION in net credit betting that uniQure's post-crash bounce won't go much higher! This sophisticated trader sold 11,000 contracts of $25 strike calls while buying 11,000 contracts of $50 strike calls, both expiring April 17, 2026 - creating a textbook bear call spread. With QURE trading at $26.36 after its catastrophic 57% crash from the FDA rejection, smart money is positioning for further downside or at least capping the upside recovery. Translation: Someone's betting $5.4M that QURE won't break above $25 by April 2026!

---

📊 Company Overview

uniQure N.V. (QURE) is a Dutch gene therapy company specializing in treatments for genetic and serious diseases:
- Market Cap: $1.88 Billion (down from ~$4B in September 2025)
- Industry: Gene Therapy / Pharmaceutical Preparations
- Current Price: $26.36 (52-week range: $5.50 - $71.50)
- Primary Business: Gene therapies for Huntington's disease (AMT-130), hemophilia B (HEMGENIX - approved), ALS, Fabry disease, and epilepsy

---

💰 The Option Flow Breakdown

The Tape (November 5, 2025 @ 10:20:28):

Time	Symbol	Side	Buy/Sell	Type	Expiration	Premium	Strike	Volume	OI	Size	Spot	Option Price
10:20:28	QURE	BID	SELL	CALL	2026-04-17	$11M	$25	11K	19K	11,000	$26.36	$10.45
10:20:28	QURE	MID	BUY	CALL	2026-04-17	$5.6M	$50	11K	22K	11,000	$26.36	$5.09

🤓 What This Actually Means

This is a BEARISH bear call spread - one of the most sophisticated ways to bet against a stock's recovery! Here's the breakdown:

• 💸 Net credit collected: $5.4M ($10.45 - $5.09 = $5.36 per spread × 11,000 contracts)
• 🎯 Short leg: Sold $25 calls (strike $1.36 below current price!) - extremely aggressive
• 🛡️ Long leg: Bought $50 calls as protection - caps losses if wrong
• ⏰ Time to expiration: 163 days (April 17, 2026)
• 📊 Max profit: $5.4M if QURE closes below $25 on expiration
• 📉 Max loss: $19.6M if QURE closes above $50 on expiration ($25 spread width - $5.36 credit = $19.64 loss per spread)
• 🎲 Breakeven: $30.36 (need QURE to stay below this level)

Unusual Score: 🔥 EXTREME (Z-scores of 1.63 and 2.43 - HIGHLY UNUSUAL size for both legs)

What's really happening here:
This trader is taking advantage of elevated implied volatility following the November 3rd FDA rejection that sent QURE plummeting 57%. By selling the $25 strike calls at-the-money and buying $50 strike calls as protection, they're betting that:

1. QURE won't meaningfully recover from the FDA setback
2. The regulatory path forward for AMT-130 (their lead drug) remains unclear
3. The stock will drift lower or stay range-bound through April 2026
4. IV will eventually collapse, letting them buy back the spread cheaper

This is NOT a retail trade - the $5.4M credit collected requires serious capital and margin. The aggressive positioning (selling calls barely out-of-the-money) shows strong conviction that the recent bounce is dead cat bounce rather than genuine recovery.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

uniQure is down -45.3% YTD with current price of $26.36. The chart tells a dramatic story - after hitting all-time lows near $3.73 in July 2024, QURE surged nearly 200% in September 2025 following positive AMT-130 trial data, only to crash 57-75% on November 3rd when the FDA reversed course on the approval pathway.

Key observations:
- 📉 Catastrophic volatility: From $5.50 to $71.50 to $26.36 in just 6 months
- 💥 FDA rejection: November 3rd crash erased $1.8B in market cap instantly
- 🎢 Dead cat bounce: Brief recovery to $26.36 appears to be fading
- 📊 Volume spike: Massive options activity suggests institutional repositioning
- ⚠️ No floor established: Still searching for support after the crash

Gamma-Based Support & Resistance Analysis

Current Price: $26.36

The gamma exposure map reveals critical price magnets and resistance walls:

🔵 Support Levels (Put Gamma Below Price):
- $20 - Strongest support with 5.6M gamma exposure (major floor post-crash)
- $12 - Secondary support at 4.8M gamma (prior accumulation zone)
- $10 - Deep support with 1.4M gamma (psychological level)

🟠 Resistance Levels (Call Gamma Above Price):
- $30 - Immediate resistance with 5.7M gamma (current battleground)
- $35 - Secondary ceiling at 6.1M gamma (gap fill target)
- $44-$49 - Minor resistance band around 0.9M gamma each
- $55 - Major resistance with -3.8M negative gamma (institutional short positioning)

What this means for traders:
QURE is trading right in the middle of no-man's-land between $20 support and $30 resistance. The strong resistance at $30 aligns perfectly with this bear call spread's breakeven - suggesting the trader did their homework. Market makers hedging this massive position will create selling pressure as QURE approaches $25-$30. The $20 support represents the "true bottom" from the FDA crash - if it breaks, next stop is the July 2024 lows around $5-$10.

Notice anything? The short call strike at $25 is positioned just below current price and well below the $30 resistance level. This trader expects the stock to either drift lower or consolidate below $25 through April 2026. The $30.36 breakeven aligns with gamma resistance, showing sophisticated positioning.

Net GEX Bias: Bullish (38.6M total gamma, but resistance overhead is formidable) - Net positioning shows more call interest above, but the negative gamma at $55 indicates heavy institutional short positioning.

Implied Move Analysis

Options market pricing for key expirations:

• 📅 December 2025 (1 month): ±$5.50 (±21%) → Range: $20.86 - $31.86
• 📅 January 2026 (2 months): ±$7.40 (±28%) → Range: $18.96 - $33.76
• 📅 April 2026 OPEX (163 days - spread expiration): ±$12.50 (±47%) → Range: $13.86 - $38.86

Translation for regular folks:
Options traders are pricing in EXTREME volatility - a 47% move by April expiration is massive even for biotech! This elevated IV is exactly why this bear call spread is attractive - the trader collected fat premiums from scared option buyers. The upper range of $38.86 is well below the $50 long call strike, suggesting the market thinks there's very low probability of recovery to pre-crash levels. The lower range of $13.86 is below the strong $20 support, indicating real fear of complete collapse if the FDA path forward is unworkable.

Key insight: The April 2026 expiration (when this spread expires) has an upper range of $38.86 - meaning even the most optimistic scenario has QURE well below the $50 long call strike. This validates the spread construction: the trader is protected against upside beyond $50, but the market is telling us that's extremely unlikely. The real battle is whether QURE stays below $25 (max profit) or drifts toward $30 (reduced profit but still winning).

---

🎪 Catalysts

🔥 Immediate Catalysts (Next 30 Days)

FDA Meeting Minutes - Expected Before December 3, 2025 📊

The FDA must provide final meeting minutes within 30 days of the November 3, 2025 regulatory update announcement. These minutes will clarify:

• 🚨 Critical question: What additional evidence does FDA require for BLA submission?
• ⚠️ Worst case: FDA requires full randomized controlled trial (RCT) adding 3-5 years
• ✅ Best case: FDA accepts modified external control approach with additional analysis
• 🎯 Most likely: FDA provides specific criteria for confirmatory evidence

Market impact: This is the single most important near-term catalyst. Clear path forward stabilizes stock; RCT requirement could send QURE to $10-15 range. Currently, management stated they were "surprised by the FDA's feedback... which is a drastic change from the guidance the FDA provided in November 2024".

Q4 2024 Financial Results - Late February 2026 💰

Expected late February 2026 based on historical reporting patterns:

• 💵 Cash position: Critical to confirm $435M cash runway through 2027 remains intact
• 📉 Burn rate: Post-restructuring (65% workforce reduction), expect ~$150M annual burn
• 💊 HEMGENIX royalties: Trend from CSL Behring partnership - baseline revenue stream
• 🔬 Pipeline spending: Any adjustments to AMT-162 (ALS), AMT-191 (Fabry), AMT-260 (epilepsy) programs

Key metric to watch: If cash runway extends beyond 2027, reduces financing risk. If burn accelerates or one-time charges appear, increases dilution risk.

🚀 Near-Term Catalysts (Q1-Q2 2026)

AMT-130 Clinical Follow-Up Data (Q1 2026) 🧬

Continued follow-up from the Phase I/II study beyond the 36-month topline data that showed 75% slowing of Huntington's disease progression:

• 📊 Durability: Does the 75% slowing persist beyond 3 years?
• 🧪 Biomarkers: CSF neurofilament light protein (NfL) trends - key FDA discussion point
• ⚠️ Safety: Any late-emerging adverse events from surgical CNS delivery
• 🎯 Efficacy signals: Additional patients reaching endpoints, subgroup analyses

Market impact: Strong durability data could provide ammunition for FDA negotiations. Safety concerns would be catastrophic for approval pathway. Neutral - stock already reflects significant uncertainty.

AMT-162 (SOD1-ALS) Phase I/II Data - H1 2026 🧠

First patient dosed October 2024, with initial data expected first half of 2026:

• 🧬 Mechanism: Intrathecal AAV9 gene therapy targeting SOD1 mutations in ALS
• 📊 Key endpoints: Safety, tolerability, preliminary efficacy signals, CSF biomarkers
• 🎯 Market: SOD1-ALS represents ~2% of ALS cases (~300-400 US patients annually)
• 🏆 Competition: Fragmented landscape, no approved gene therapies for ALS yet

Market impact: Positive data provides pipeline diversification away from AMT-130 dependency. Failure would further undermine gene therapy platform credibility. Upside potential moderate - already built into "pipeline optionality" valuation component.

🤖 Medium-Term Catalysts (6-12 Months)

AMT-191 (Fabry Disease) Phase I/IIa Data - 2026 🫀

First patient dosed August 2024, granted Orphan Drug and Fast Track designations:

• 🧬 Target: Alpha-galactosidase A enzyme deficiency causing Fabry disease
• 📊 Endpoints: Safety, enzyme levels, clinical symptom improvement
• 🏥 Market: Ultra-orphan indication, ~1 in 40,000 births
• ✅ Regulatory: Fast Track designation accelerates development and review

AMT-260 (Temporal Lobe Epilepsy) Interim Data - 2026 🧠

First patient dosed November 2024:

• 🧬 Mechanism: AAV9 delivering miRNA to silence GRIK2 gene
• 📊 Key metric: Seizure frequency reduction in drug-resistant epilepsy
• 🏥 Market: Mesial temporal lobe epilepsy affects ~150,000 US patients with drug-resistant disease
• ⚠️ Delivery: Direct surgical delivery to temporal lobe - invasive but potentially curative

Market impact: Both programs represent "shots on goal" beyond AMT-130. Positive data in either could partially offset AMT-130 setback. But neither has near-term commercial potential - earliest approval would be 2028-2029.

📱 Long-Term Catalysts (12-24+ Months)

HEMGENIX Commercial Trajectory 💊

FDA approved November 2022 - first gene therapy for hemophilia B:

• 💰 Pricing: $3.5 million per dose (most expensive medication at launch)
• 🤝 Partner: CSL Behring handles commercialization; uniQure receives royalties
• 📊 Market size: ~5,000-6,000 US hemophilia B patients eligible
• 💵 Revenue: uniQure sold portion of royalty rights for $375M upfront in May 2023
• 📈 Growth: Hemophilia B gene therapy market projected $0.51B (2023) → $3.43B (2032)

Ongoing catalyst: Quarterly royalty revenue provides baseline cash flow but limited growth driver. Competition from Pfizer's Phase III program expected 2025-2026 approval could pressure market share.

Business Development / Pipeline Expansion 🤝

• 💰 Financial capacity: $435M cash provides optionality for in-licensing
• 🧬 Platform: Proprietary baculovirus-insect cell AAV production system differentiates
• 🌍 Geographic expansion: Potential regional licensing deals for existing programs
• ⚠️ Risk: Post-FDA rejection, potential partners may demand discounted terms

Probability: Moderate - company needs to demonstrate regulatory execution capability before attracting premium partnerships.

⚠️ Risk Catalysts (Negative)

Randomized Controlled Trial (RCT) Requirement ⚖️

Timeline impact: If FDA requires full RCT for AMT-130:
- 📅 Study design & startup: 6-12 months
- 📅 Patient enrollment: 18-24 months (Huntington's is rare, progressive disease makes recruitment challenging)
- 📅 Follow-up duration: 24-36 months minimum
- 📅 Data analysis & BLA: 6-12 months
- ⏰ Total delay: 4.5-6 years added to approval timeline (pushing to 2029-2031)

Financial impact:
- 💸 RCT cost: $150-300M for multi-center, international study
- 🏦 Cash runway: Current $435M only extends through 2027 - would require financing in 2025-2026
- 📉 Dilution: Stock trading at depressed $26.36 level creates massive dilution risk
- ⚠️ Execution risk: 65% workforce reduction may impair ability to run complex global trial

Market impact: Announcement of RCT requirement could send QURE to $10-15 range. This would be catastrophic for near-term valuation but doesn't necessarily mean AMT-130 is dead - just very delayed.

Pipeline Program Failures 🧪

If AMT-162 (ALS), AMT-191 (Fabry), or AMT-260 (epilepsy) show safety issues or lack efficacy:
- 📊 Platform credibility: Multiple failures would question AAV delivery platform
- 💰 Sunk costs: Millions invested in each program with no return
- 🎯 Strategic pivot: May force company to consider M&A or partnership at unfavorable terms

Competitive Losses 🏆

Roche/Spark's RG6662 and Voyager/Novartis programs advancing in Huntington's disease:
- 🏢 Resource advantage: Roche has far deeper pockets and regulatory expertise
- 🎯 First-mover lost: FDA rejection eliminated uniQure's head start
- 📊 Winner-take-most: Rare disease markets typically dominated by first-to-market

---

🎲 Price Targets & Probabilities

Using gamma levels, catalyst timeline, and FDA regulatory uncertainty, here are the scenarios:

📉 Bear Case (45% probability)

Target: $10-$18

How we get there:
- 😱 FDA requires full RCT for AMT-130, adding 4-5 years to timeline
- 💸 Company forced into dilutive financing at depressed valuations in 2026
- 🧪 One or more pipeline programs (AMT-162, AMT-191, AMT-260) show safety issues
- 🏆 Competitor (Roche/Spark) advances ahead in Huntington's disease
- 📉 HEMGENIX royalties disappoint as Pfizer hemophilia B gene therapy gains traction
- ⚠️ Break below $20 gamma support triggers cascade selling to $12 or lower
- 💔 Insider selling continues (244K shares sold, zero bought in past 3 months signals management concern)

Key risk factors: Stock could retest July 2024 all-time lows near $5.50 if AMT-130 path proves uneconomical. The 66-79% institutional ownership creates risk of forced redemptions if funds capitulate.

This scenario makes the bear call spread profitable: Stock stays well below $25, trader keeps full $5.4M credit.

🎯 Base Case (40% probability)

Target: $18-$30 range

Most likely scenario:
- ⚖️ FDA clarifies path forward requiring additional evidence but not full RCT
- 📊 Modified external control approach accepted with confirmatory data package
- 💰 Cash runway confirmed through 2027, reduces immediate financing pressure
- 🧬 AMT-130 follow-up data remains positive, supporting regulatory negotiations
- 📈 One pipeline program (AMT-162 or AMT-191) shows encouraging Phase I/II signals
- 💊 HEMGENIX royalties stable, providing baseline revenue
- 🔄 Trading range-bound between $20 gamma support and $30 resistance
- ⏰ BLA submission timeline pushed to late 2026 or early 2027 (vs original Q1 2026)

This is the spread's breakeven zone: If QURE drifts toward $30, the trader starts giving back some of the $5.4M credit collected. But staying below $25 = max profit.

Catalysts to watch:
- December FDA meeting minutes clarity
- February 2026 financial results confirming burn rate
- H1 2026 AMT-162 (ALS) early data

📈 Bull Case (15% probability)

Target: $40-$60

What needs to happen:
- 🚀 FDA provides surprise clarity that modified approval pathway is viable
- 💪 AMT-130 additional data strengthens regulatory case significantly
- ✅ BLA submission maintained for 2026 with accelerated approval pathway intact
- 🧬 AMT-162 or AMT-191 data "home run" creates pipeline validation
- 💰 Strategic partnership or licensing deal announced at premium terms
- 📊 HEMGENIX royalties exceed expectations, CSL reports strong adoption
- 🎯 Positive analyst upgrades shift sentiment from "regulatory disaster" to "temporary setback"
- 📈 Break through $30 resistance on sustained buying, target $35-$44 gap fill zone

Key technical levels: Need to decisively break $30 resistance and $35 gamma wall to reach $40-60 range. The strong negative gamma at $55 (-3.8M) represents heavy institutional short positioning - short squeeze possible but requires multiple positive catalysts aligning.

This scenario hurts the spread: Stock above $30 starts eroding the $5.4M credit. Above $50 = max loss of $19.6M (but capped by long calls). However, probability is low - market is pricing only 15% chance of recovery to pre-crash levels.

---

💡 Trading Ideas

🛡️ Conservative: Stay Far Away Strategy

Play: Avoid QURE entirely until regulatory clarity emerges

Why this makes sense:
- ⏰ FDA meeting minutes expected within 30 days - massive binary risk
- 🎲 Outcome range is $10-60 - that's 6x swing potential in either direction!
- 😰 11-17% short interest means volatility will be extreme on any news
- 📊 Already down 45% YTD with 57% single-day crash in November - this is NOT a "safe" biotech
- 💸 Even sophisticated institutions getting crushed (66-79% institutional ownership likely underwater)

Action plan:
- 👀 Wait for December FDA meeting minutes before even considering entry
- 🎯 If FDA path forward is viable, wait for pullback to $20 support for risk/reward
- ⚠️ If FDA requires RCT, wait for capitulation selling to $10-15 before bottom-fishing
- 📊 Monitor insider buying (currently ZERO) - when insiders buy, that's your signal

Risk level: Minimal (cash position) | Skill level: Beginner-friendly

Reality check: This is a binary biotech bet disguised as a stock. Unless you can stomach losing 50%+ overnight on regulatory news, this isn't for you.

⚖️ Balanced: Post-Clarity Bull Put Spread

Play: AFTER FDA meeting minutes, if path forward identified, sell bull put spread

Structure: Buy $15 puts, Sell $20 puts (January 2026 expiration)

Why this could work:
- 🛡️ Only enter if FDA provides workable path (not RCT requirement)
- 📊 Defined risk spread - max loss $5 per spread ($500 per contract)
- 🎯 Targets strong gamma support at $20 where dealer hedging creates floor
- 💸 Collect premium from elevated IV while betting on stabilization
- ⏰ 2-month duration captures potential dead cat bounce momentum

Estimated P&L (wait for actual IV before sizing):
- 💰 Collect ~$1.50-2.00 credit per spread (net risk of $3.00-3.50)
- 📈 Max profit: $150-200 per spread if QURE stays above $20
- 📉 Max loss: $300-350 per spread if QURE breaks below $15
- 🎯 Breakeven: ~$18-18.50

Entry conditions (ALL must be met):
1. ✅ FDA meeting minutes show viable path forward (not full RCT)
2. ✅ Stock stabilizes above $22 for 3+ days post-news
3. ✅ Put volume and open interest suggest defensive positioning (not panic)
4. ✅ Analyst commentary shifts from "avoid" to "speculative buy"

Exit strategy:
- 🎯 Take profit at 50% of max gain ($75-100 per spread)
- ⚠️ Cut losses if stock breaks $22 support with volume (don't wait for max loss)
- ⏰ Close 2 weeks before expiration to avoid gamma risk

Risk level: Moderate (defined risk, requires catalyst confirmation) | Skill level: Intermediate

WARNING: Do NOT enter this trade if FDA requires RCT. That's a $10-15 stock, and your $15-20 put spread will get demolished.

🚀 Aggressive: Mimic the Smart Money Bear Call Spread (HIGH RISK!)

Play: Copy the exact trade structure from this flow

Structure: Sell $25 calls, Buy $50 calls (April 17, 2026 expiration)

Why this could work:
- 💰 Collect fat premium from terrified option buyers (~$5.36 per spread)
- 📊 IV likely remains elevated through December FDA meeting, then IV crush accelerates profit
- 🎯 Betting with sophisticated money that positioned $5.4M credit
- ⏰ 163 days gives plenty of time for IV to collapse and stock to drift lower
- 📉 Technical setup supports: resistance at $30, gamma ceiling at $35, weak recovery bounce

Why this could blow up (SERIOUS RISKS!):

💥 DEFINED BUT LARGE RISK - Max loss is $19.64 per spread ($1,964 per full spread):
- 😱 Need $1,964 in margin per spread (vs $536 credit) - capital intensive
- 🚀 If FDA surprises with positive pathway and stock rallies to $50+, you lose 3.7x your credit
- ⚠️ Stock trading at $26.36 means short $25 calls are already IN THE MONEY - assignment risk!
- 💸 Early assignment possible if calls go deeper ITM - need to manage actively
- 🎲 Binary FDA catalyst risk - could gap up or down 30-50% on single announcement
- 📊 If wrong on direction, losses accelerate quickly above $30 (your breakeven)

Estimated P&L:
- 💰 Collect ~$536 credit per spread (sell $25 call ~$10.45, buy $50 call ~$5.09)
- 📈 Max profit: $536 if QURE closes below $25 at April expiration (keep full credit)
- 📉 Max loss: $1,964 if QURE closes above $50 (width $25 - credit $5.36 = $19.64 loss)
- 🎯 Breakeven: $30.36 per share

Position sizing:
- ⚠️ Start with 1-2 spreads MAXIMUM ($536-1,072 credit, $1,964-3,928 max risk)
- 💰 Set aside 3x your credit as reserve capital ($1,608 per spread)
- 📊 This should be <5% of total portfolio due to binary risk

Entry timing:
- ⏰ WAIT for initial FDA meeting minutes (expected before December 3rd)
- ✅ Only enter if FDA requires extensive additional work (RCT or modified approach with delays)
- 🚫 DO NOT enter if FDA provides clear fast path or if stock breaks above $30

Risk level: HIGH (large defined loss potential, binary catalyst risk) | Skill level: Advanced only

⚠️ WARNING: DO NOT attempt this trade unless you:
- Have experience managing short options through binary biotech catalysts
- Can actively monitor and adjust position daily
- Can afford max loss of $1,964 per spread without impacting your lifestyle
- Understand this is a bet that FDA news remains negative and stock drifts lower
- Have margin approval for spreads (broker will require capital hold)

Why this is different from typical spreads:
Unlike safer spreads with short strikes well out-of-the-money, this bear call spread has the short leg already IN THE MONEY at current prices. The max loss ($1,964) is 3.7x larger than the credit collected ($536), and you're selling calls that could be assigned at any time. The trader who put up $5.4M clearly has conviction and capital - make sure you do too before copying.

---

⚠️ Risk Factors

Don't get caught by these potential landmines:

• 🚨 Binary FDA catalyst in 30 days: Meeting minutes expected before December 3rd will determine if AMT-130 has viable path to approval or requires prohibitively expensive RCT. Stock could gap 30-50% either direction on clarity. Historical precedent: November 3rd announcement caused 57% single-day crash.

• ⚖️ Regulatory execution disaster already happened: FDA's November 3rd reversal on approval pathway was described by CEO as "a drastic change from the guidance the FDA provided in November 2024." This demonstrates regulatory unpredictability and undermines management credibility. FDA may not provide clear path forward even after meeting minutes.

• 💸 Single asset dependency is now confirmed risk: 60-80% of company valuation was tied to AMT-130. With lead program in jeopardy, remaining value is pipeline optionality (AMT-162, AMT-191, AMT-260) that won't generate revenue until 2028-2029 at earliest. HEMGENIX royalties provide baseline but limited growth.

• 🧬 External control methodology rejected - precedent risk: FDA's rejection of Enroll-HD database as external control despite prior agreement signals potential policy shift. This could affect other rare disease gene therapy programs industry-wide. May indicate FDA is tightening standards post-approval of early gene therapies that had mixed commercial/safety results.

• 💰 Cash runway crunch if RCT required: Current $435M extends through 2027 with current burn rate. But RCT would cost $150-300M and take 4-5 years, requiring dilutive financing in 2025-2026 at depressed stock price. Stock trading at $26.36 (down from $71.50 high) means massive shareholder dilution from any raise.

• 🏆 Competitors have resource advantage: Roche/Spark and Voyager/Novartis Huntington's programs backed by Big Pharma resources. FDA rejection leveled playing field - uniQure's first-mover advantage eliminated. Winner-take-most dynamics in rare disease market.

• 📊 Extreme volatility - not for weak hands: 30-day realized volatility at 27.73%, with 52-week range of $5.50-$71.50 (13x range!). November 3rd crash erased 57% in single day. Options traders pricing in 47% implied move by April 2026. This is a binary bet, not a stock investment.

• 💔 Insider selling signals concern: 244K shares sold, ZERO shares bought in past 3 months. Management saw the FDA reversal coming and got out. When insiders won't buy at these "cheap" levels, that's a massive red flag.

• 🎯 No floor until $20, then $12, then $5: Gamma support at $20 is only support level that matters. Break below that, next stop is $12 (July accumulation zone), then $5.50 (all-time low). No fundamental support until cash per share (~$8-9 per share based on $435M cash and 49M shares).

• 📉 Short interest creates explosive volatility: 11-17% of float short means any positive catalyst could trigger violent short squeeze to $40-50. Conversely, any negative catalyst gets amplified by short sellers piling on. This creates whipsaw action that destroys option positions on both sides.

---

🎯 The Bottom Line

Real talk: Someone just bet $5.4 MILLION that uniQure's dead cat bounce after the FDA catastrophe is over. They're not buying puts or shorting stock - they're selling calls barely out-of-the-money and collecting massive premium from terrified option buyers. That's the ultimate contrarian bearish position.

What this trade tells us:
- 🎯 Sophisticated institutional player expects QURE to stay below $25-30 through April 2026
- 💰 They're taking advantage of sky-high IV following the 57% crash to collect $5.4M in premium
- ⚖️ Risk/reward attractive when IV is elevated and regulatory outlook is murky
- 📊 Similar to selling insurance after a disaster - premiums are fat but risks are real

If you own QURE:
- 😱 SERIOUSLY CONSIDER EXITING if you don't have stomach for binary biotech risk
- 📊 Strong technical support at $20, but that's 24% below current price
- ⏰ If you're holding through FDA meeting minutes (masochist), set mental stop at $22
- 🎯 Only stay long if you believe in:
1. FDA will accept modified approval pathway (not RCT)
2. AMT-130 data compelling enough to overcome regulatory skepticism
3. Management can execute despite 65% workforce reduction
4. Pipeline programs provide meaningful optionality
- 💰 If all above true, $40-60 recovery possible on positive clarity (but 15% probability)

If you're watching from sidelines:
- ⏰ December FDA meeting minutes - this is the catalyst that matters
- 🎯 If FDA requires RCT → wait for capitulation to $10-15, then consider bottom-fishing
- ✅ If FDA provides viable path → wait for initial pop to fade, enter at $20-22 support
- 🚫 If FDA remains unclear → stay away, this becomes dead money for months
- 📈 Best case entry is "bad news that's less bad than feared" creating selling exhaustion

If you're bearish:
- 📊 This bear call spread structure makes sense - defined risk, high probability profit
- ⚠️ But the margin requirement ($1,964 max loss vs $536 credit) is steep
- 🎯 Alternative: Buy $20 puts (January 2026) if FDA news confirms RCT requirement
- 💰 Put spreads offer better capital efficiency than bear call spread for directional bearish bet
- ⏰ Timing is critical: Wait for FDA clarity, don't fight potential dead cat bounce

Mark your calendar - Key dates:
- 📅 Before December 3, 2025 - FDA meeting minutes expected (30 days from November 3rd announcement)
- 📅 Late February 2026 - Q4 2024 and Full Year 2024 financial results
- 📅 H1 2026 (April-June) - AMT-162 (SOD1-ALS) Phase I/II initial data
- 📅 April 17, 2026 - This bear call spread expires
- 📅 2026 - AMT-191 (Fabry) and AMT-260 (Epilepsy) interim data (dates TBD)

Final verdict: This is a sophisticated bearish bet by institutional money that the FDA disaster is real and the recovery bounce is temporary. The trade structure (bear call spread) shows conviction with defined risk - they're not recklessly shorting with unlimited exposure. For retail investors, the lesson is simple: when a biotech's lead program gets FDA rejected after previous agreement, the regulatory path forward is unclear for months/years. That makes it uninvestable until clarity emerges. The 47% implied volatility by April 2026 tells you everything - the market has NO IDEA where this stock will be in 5 months. That's not a stock, that's a binary bet.

Probability-weighted assessment:
- 45% probability: $10-18 bear case (RCT requirement or worse)
- 40% probability: $18-30 base case (modified path with delays)
- 15% probability: $40-60 bull case (surprise positive resolution)
- Expected value: ~$22 (risk skewed to downside)

Current price of $26.36 suggests market is more optimistic than this analysis, or there's hope the December FDA minutes provide better-than-expected clarity. The bear call spread trader is betting against that optimism.

Disclaimer: Biotech investing carries extreme risk of total loss. Options trading on binary catalyst stocks can result in 100% loss of premium paid or substantial losses on spread positions. This analysis is for educational purposes only and not financial advice. The unusual options activity described does not constitute a recommendation to follow the trade. Always conduct your own due diligence and consult a licensed financial advisor before trading. Binary FDA catalysts create gap risk that can exceed defined risk parameters if positions are not actively managed.

---

About uniQure N.V.: uniQure is a Dutch gene therapy company with a $1.88 billion market cap, specializing in treatments for genetic and serious diseases including Huntington's disease, hemophilia B, ALS, Fabry disease, and epilepsy in the Pharmaceutical Preparations industry.